Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta‐Analysis

2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation

(2019) Craig T. January et al.   CIRCULATION

Global rising trends of atrial fibrillation: a major public health concern

(2018) Nileshkumar J Patel et al.   HEART

CHA2DS2-VASc score and risk of thromboembolism and bleeding in patients with atrial fibrillation and recent cancer

(2018) Maria D’Souza et al.   European Journal of Preventive Cardiology

To teach an old dog new tricks: The limits of CHA2DS2-VASc in patients with atrial fibrillation and cancer

(2018) Xiaoxi Yao et al.   European Journal of Preventive Cardiology

Effect of Non-vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients with Newly Diagnosed Cancer

(2018) Kyu Kim et al.   Korean Circulation Journal

Patients with cancer and atrial fibrillation treated with doacs: A prospective cohort study

(2018) Maria Cristina Vedovati et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Atrial Fibrillation and Malignancy: The Clinical Performance of Non–Vitamin K Oral Anticoagulants—A Systematic Review

(2018) Roberta Bottino et al.   SEMINARS IN THROMBOSIS AND HEMOSTASIS

Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF‐TIMI 48 Trial

(2018) Christina L. Fanola et al.   Journal of the American Heart Association

Administration of direct oral anticoagulants in patients with myeloproliferative neoplasms

(2017) Jean-Christophe Ianotto et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Risk of Arterial Thromboembolism in Patients With Cancer

(2017) Babak B. Navi et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

A re-evaluation of fixed effect(s) meta-analysis

(2017) Kenneth Rice et al.   JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES A-STATISTICS IN SOCIETY

Anticoagulation prescribing patterns in patients with cancer

(2017) Elaine Xiang et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

Use of Non–Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients with Malignancy: Clinical Practice Experience in a Single Institution and Literature Review

(2017) Anna Rago et al.   SEMINARS IN THROMBOSIS AND HEMOSTASIS

P-024: Direct oral anticoagulation (DOACs) in women with active cancer and atrial fibrillation (AF): a good example of personalised anticoagulation

(2017) A. Varela-Magallon et al.   THROMBOSIS RESEARCH

Effects of Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta‐Analysis

(2017) Kuo‐Li Pan et al.   Journal of the American Heart Association

Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: a Danish nationwide population-based cohort study

(2017) Anne G. Ording et al.   Cancer Medicine

Single-center, retrospective evaluation of safety and efficacy of direct oral anticoagulants versus low-molecular-weight heparin and vitamin K antagonist in patients with cancer

(2017) Elizabeth R Pritchard et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Are New Oral Anticoagulants Ready for Use in Patients With Cancer?

(2017) Paul C. Hendrie et al.   Journal of the National Comprehensive Cancer Network

Antithrombotic Therapy for VTE Disease

(2016) Clive Kearon et al.   CHEST

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

(2016) Paulus Kirchhof et al.   EUROPEAN HEART JOURNAL

Atrial fibrillation as risk factor for cardiovascular disease and death in women compared with men: systematic review and meta-analysis of cohort studies

(2016) Connor A Emdin et al.   BMJ-British Medical Journal

Atrial fibrillation as risk factor for cardiovascular disease and death in women compared with men: systematic review and meta-analysis of cohort studies

(2016) Connor A Emdin et al.   BMJ-British Medical Journal

The HAS-BLED Score for Predicting Major Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: A Systematic Review and Meta-analysis

(2015) Wengen Zhu et al.   CLINICAL CARDIOLOGY

Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014

(2015) Gary H. Lyman et al.   JOURNAL OF CLINICAL ONCOLOGY

Meta-Analysis of CHADS2versus CHA2DS2-VASc for Predicting Stroke and Thromboembolism in Atrial Fibrillation Patients Independent of Anticoagulation

(2015) Wen-Gen Zhu et al.   TEXAS HEART INSTITUTE JOURNAL

The Clinical Profile and Pathophysiology of Atrial Fibrillation

(2014) Jason Andrade et al.   CIRCULATION RESEARCH

Worldwide Epidemiology of Atrial Fibrillation

(2013) Sumeet S. Chugh et al.   CIRCULATION

Edoxaban versus Warfarin in Patients with Atrial Fibrillation

(2013) Robert P. Giugliano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Uso del tratamiento antitrombótico según la escala CHA2DS2-VASc en los pacientes con fibrilación auricular en atención primaria

(2013) Vivencio Barrios et al.   REVISTA ESPANOLA DE CARDIOLOGIA

Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients

(2012) Yu-feng Hu et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Apixaban versus Warfarin in Patients with Atrial Fibrillation

(2011) Christopher B. Granger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

(2011) Manesh R. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiovascular Risk in Clopidogrel-Treated Patients According to Cytochrome P450 2C19*2 Loss-of-Function Allele or Proton Pump Inhibitor Coadministration

(2010) Jean-Sébastien Hulot et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   PLOS MEDICINE